What To Do If Your Compounded Microdose Is Discontinued

If you have been microdosing compounded semaglutide or tirzepatide and just got an email that your program is pausing, raising prices, or "transitioning" you — this is happening across the market, and it is not random. The compounded supply that made microdosing cheap and easy is being switched off in 2026, on a regulatory timeline. This is a practical, non-alarmist guide to what your real options are. None of it is medical advice; every path below should be walked with a clinician.

Why your supply is going away

Compounded GLP-1 only existed at scale because semaglutide and tirzepatide were in declared shortages. Those shortages are over — tirzepatide's resolved in December 2024, semaglutide's in February 2025 — and in May 2026 the FDA proposed to keep both molecules (plus liraglutide) off the 503B bulks list, with a comment period through June 29, 2026. If finalized, that closes the large-scale outsourcing pathway most telehealth microdose programs run on. The full timeline and the surviving 503A carve-out are laid out in is compounded microdose GLP-1 still legal in 2026.

The practical consequence: through 2026, expect bulk-compounding sources to dry up, some telehealth labs to stop dispensing entirely, and the programs that continue to look very different (and usually cost more). The honest backdrop is that microdosing was never a tested protocol to begin with — the clinical literature describes it as a practice that "emerged amid GLP-1 compounding restrictions," built on anecdote rather than trials¹. So a forced transition is also a reasonable moment to ask whether to continue at all.

Step one: do not abruptly run out and panic

A discontinuation notice is not an emergency, but it is a prompt to plan rather than to scramble. Two things to know:

• •GLP-1 effects are not permanent, and stopping has predictable consequences. When people came off full-dose semaglutide in the STEP 1 trial extension, they regained roughly two-thirds of their lost weight over the following year and saw cardiometabolic markers drift back². At microdoses the effect — and therefore the rebound — is smaller, but the direction is the same: this is a maintenance strategy, not a cure.
• •There is no withdrawal-style danger to stopping, but appetite and any benefits typically return. So the choice is really about what you want next, not about avoiding harm from stopping.

If you decide to come off, do it deliberately. We walk through it in how to taper off GLP-1.

Your four realistic paths

1. Taper off and stop. Legitimate if your goals are met or you have decided the unproven microdose strategy is not worth the cost and hassle. Plan for appetite to return and build the lifestyle scaffolding to hold your results. See how to taper off GLP-1.

2. Move to a maintenance approach. If a low dose was working for you, the question becomes how to sustain it through a tighter supply. We cover the realistic options — including lower-frequency dosing and what "maintenance" actually means without a compounded vial — in microdosing GLP-1 for maintenance.

3. Pivot to an FDA-approved oral GLP-1. This is the genuinely new option in 2026. Oral semaglutide at the obesity dose (Rybelsus is the diabetes brand; a 50 mg once-daily obesity formulation was studied in OASIS 1, producing about 15% weight loss over 68 weeks³) gives a needle-free, FDA-approved route — though at full, not micro, dosing. We cover the oral-semaglutide path and its real bioavailability quirks in microdose Rybelsus / oral semaglutide. And orforglipron, a once-daily oral small-molecule GLP-1, now has phase 3 data behind it, including a maintenance trial showing it sustained weight reduction versus placebo after an initial loss⁴ — an approved pill is a very different proposition from a compounded vial.

4. Move to an FDA-approved injectable (Wegovy or Zepbound) — possibly at a deliberately low dose. The approved pens start at low titration doses anyway. Working with a clinician to use a branded pen carefully is the most defensible way to keep a "low-dose" strategy alive once compounding closes; the dose math is in how many units is a microdose in an Ozempic or Wegovy pen.

What about staying compounded through a 503A pharmacy?

This is possible but narrow. The 503A patient-specific pathway survives, but only with a documented, individual clinical reason — an allergy to an inactive ingredient, a genuinely needed dosage form the manufacturer does not make. Wanting a cheaper or lower "microdose" of an available drug is not, by itself, a recognized clinical need. Do not assume a pharmacy can simply keep compounding for you; ask a licensed pharmacist directly. The legal boundaries are detailed in is compounded microdose GLP-1 still legal in 2026.

How to choose

The right path depends on why you were microdosing in the first place. If it was cost, an approved oral or a low titration dose of a brand pen may now be competitive — compare honestly in what microdosing GLP-1 costs. If it was tolerability, the approved drugs all start low and titrate slowly. If it was genuine metabolic need, that is exactly the conversation to bring to a clinician — and the case for an FDA-approved, monitored option rather than a grey-market workaround.

For the bigger picture on whether the strategy was doing anything at all, read our pillar, microdosing GLP-1 — what the evidence actually shows, and to vet whatever program you land on next, the GLP-1 microdose rankings hub and our best microdose GLP-1 providers guide. A supply disruption is unsettling, but in 2026 you have more legitimate, FDA-approved routes than microdosers had a year ago.